Abstract:Seho Kweon, 1, 2 Seong Jin Park, 3 Ha Kyeong Lee, 1 Seo Hee Kang, 4 Kwan-Young Chang, 4 Jeong Uk Choi, 5 Jooho Park, 6 Jung-Hyun Shim, 7 Jin Woo Park, 7 Youngro Byun 1, 3 1 Department of Molecular Medicine and Biopharmaceutical Science, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, 08826, Republic of Korea; 2 College of Pharmacy, Chonnam National University, Gwangju, 61186, Republic of Korea; 3 College of Pharmacy, Seoul National University, Seoul, 08826, Republic of Korea; 4 Global R&D Center, IcureBNP, Seoul, 06170, Republic of Korea; 5 College of Pharmacy, Kyung Hee University, Seoul, 02447, Republic of Korea; 6 Department of Biomedical & Health Science, Konkuk University, Chungju, 27478, Republic of Korea; 7 College of Pharmacy and Biomedical and Healthcare Research Institute, Mokpo National University, Jeonnam, 58554, Republic of Korea Correspondence: Jin Woo Park; Youngro Byun, Tel +82 61 450 2704, Email ; Background: For maintenance therapy in type 2 diabetes, glucagon-like peptide-1 agonist (GLP-1A), which exhibits low cardiovascular risk and high efficacy, is a promising peptide therapeutic. However, developing an oral GLP-1A presents challenges due to the analog's poor cellular permeability and gastrointestinal (GI) stability. Methods: To mitigate such limitations, an oral nanoformulation of liraglutide (LG) was designed and achieved by combining LG with bile acid derivatives using the nanoprecipitation method. This strategy allowed the bile acid moieties to localize at the nanoparticle surface, enhancing the binding affinity for apical sodium-dependent bile acid transporter (ASBT) and improving GI stability. The in vitro characteristics, cellular permeability, and absorption mechanisms of the LG nanoformulation (LG/TD-NF) were thoroughly investigated. Furthermore, the in vivo oral absorption in rats and the glucose-lowering effects in a diabetic ( db/db ) mouse model were evaluated. Results: The LG/TD-NF produced neutral nanoparticles with a diameter of 58.7 ± 4.3 nm and a zeta potential of 4.9 ± 0.4 mV. Notably, when exposed to simulated gastric fluid, 65.7 ± 3.6% of the LG/TD-NF remained stable over 120 min, while free LG was fully degraded. Relative to unformulated LG, the Caco-2 cellular permeability of the nanoformulation improved, measuring 10.9 ± 2.1 (× 10 − 6 cm/s). The absorption mechanism prominently featured endocytosis simultaneously mediated by both ASBT and epidermal growth factor receptor (EGFR). The oral bioavailability of the LG/TD-NF was determined to be 3.62% at a dosage of 10 mg/kg, which is 45.3 times greater than that of free LG. In a diabetes model, LG/TD-NF at 10 mg/kg/day exhibited commendable glucose sensitivity and reduced HbA1c levels by 4.13% within 28 days, similar to that of subcutaneously administered LG at a dosage of 0.1 mg/kg/day. Conclusion: The oral LG/TD-NF promotes ASBT/EGFR-mediated transcytosis and assures cellular permeability within the GI tract. This method holds promise for the development of oral GLP-1A peptides as an alternative to injections, potentially enhancing patient adherence to maintenance therapy. Keywords: nanoformulation of GLP-1A, oral liraglutide, ASBT-mediated endocytosis, EGFR Type 2 diabetes mellitus (T2DM) is a chronic disease characterized by inadequate insulin production, and in some instances, a decline in insulin sensitivity as the condition progresses. 1 Orally administered pharmacological agents, such as metformin, dipeptidyl peptidase-4 inhibitors, and sodium-glucose cotransporter-2 inhibitors, are extensively utilized as potential therapeutic interventions for T2DM management in the context of long-term treatment. Moreover, injectable therapeutic peptides, including glucagon-like peptide-1 agonist (GLP-1A) and insulin, often serve as primary treatment modalities. 2,3 Due to their superior glucose-lowering effects and reduced cardiovascular risks compared to chemical-based medications, these therapeutic peptides have garnered significant attention in drug development. Thus, there is an intensified focus on advancing synthesis and purification technologies to further the development of these peptides. 4 However, the need for prolonged and frequent invasive administration can lead to decreased patient compliance and heightened risk for infections, potentially resulting in treatment failure. Several modified forms of GLP-1A have been introduced to mitigate these limitations. Some of these have extended half-lives, such as liraglutide (LG), lixisenatide, albiglu -Abstract Truncated-

Oral Delivery of Liraglutide-Loaded Zein/Eudragit-Chitosan Nanoparticles Provides Pharmacokinetic and Glycemic Outcomes Comparable to Its Subcutaneous Injection in Rats

Intestinal Epithelium Penetration of Liraglutide Via Cholic Acid Pre-Complexation and Zein/rhamnolipids Nanocomposite Delivery

Double Layer Spherical Nanoparticles with Hyaluronic Acid Coating to Enhance Oral Delivery of Exenatide in T2DM Rats.

Sulfobetaine modification of poly (D, L-lactide-co-glycolic acid) nanoparticles enhances mucus permeability and improves bioavailability of orally delivered liraglutide

Coordinated ASBT and EGFR Mechanisms for Optimized Liraglutide Nanoformulation Absorption in the GI Tract

Zein-Based Nanoparticles as Oral Carriers for Insulin Delivery

Effective and safe delivery of GLP-1AR and FGF-21 plasmids using amino-functionalized dual-mesoporous silica nanoparticles <i>in vitro</i> and <i>in vivo</i>

Effective and safe delivery of GLP-1AR and FGF-21 plasmids using amino-functionalized dual-mesoporous silica nanoparticles in vitro and in vivo

Injectable and Thermosensitive Hydrogel Containing Liraglutide As a Long-Acting Antidiabetic System

A polyphenol-metal nanoparticle platform for tunable release of liraglutide to improve blood glycemic control and reduce cardiovascular complications in a mouse model of type II diabetes

Preparation of chitosan-based multifunctional nanocarriers overcoming multiple barriers for oral delivery of insulin.

Effective oral delivery of Exenatide-Zn2+ complex through distal ileum-targeted double layers nanocarriers modified with deoxycholic acid and glycocholic acid in diabetes therapy

Oral delivery of exenatide-loaded hybrid zein nanoparticles for stable blood glucose control and β-cell repair of type 2 diabetes mice

Insulin- and Cholic Acid-Loaded Zein/casein-Dextran Nanoparticles Enhance the Oral Absorption and Hypoglycemic Effect of Insulin.

Enteric-coated capsules filled with mono-disperse micro-particles containing PLGA-lipid-PEG nanoparticles for oral delivery of insulin

Oral delivery of the amylin receptor agonist pramlintide

Preparation and characterization of BSA-loaded liraglutide and platelet fragment nanoparticle delivery system for the treatment of diabetic atherosclerosis

482-P: The GLP-1 Receptor Agonist Liraglutide Improves Glomerular Filtration Rate, Renal Inflammation, and Fibrosis in the Type 2 Diabetic SDT Fatty Rat

Fat fighting liraglutide based nano-formulation to reverse obesity: Design, development and animal trials

Controlled release of liraglutide using thermogelling polymers in treatment of diabetes

Preparation, characterization, and oral delivery of insulin loaded carboxylated chitosan grafted poly(methyl methacrylate) nanoparticles.